Asundexian added to antiplatelet therapy reduces recurrent stroke risk without increasing major bleeding in high-risk patients.
New drug lowers stroke risk in high-risk patients without increasing bleeding
This phase 3 trial evaluated asundexian added to standard antiplatelet therapy in patients with noncardioembolic ischemic stroke or high-ris…
A new daily pill lowers stroke risk in high-risk patients without increasing bleeding, offering a safer option for preventing clots after a …
Post hoc analysis finds cilostazol reduces stroke recurrence without lowering systolic blood pressure
Study finds cilostazol reduces stroke recurrence without lowering blood pressure
A post hoc mediation analysis of an RCT in 1,795 patients with noncardioembolic ischemic stroke found dual therapy with cilostazol plus aspi…
Cilostazol lowers stroke recurrence risk in patients with prior noncardioembolic strokes without working by dropping their blood pressure.